Article citationsMore>>

Buiten, R.A., Ploumen, E.H., Zocca, P., Doggen, C.J., Jessurun, G.A., Schotborgh, C.E., Roguin, A., Danse, P.W., Benit, E., Aminian, A. and van Houwelingen, K.G. (2020) Thin Composite-Wire-Strut Zotarolimus-Eluting Stents versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years. JACC: Cardiovascular Interventions, 13, 1100-1109.
https://doi.org/10.1016/j.jcin.2020.01.230

has been cited by the following article:

• TITLE: All-Comers Study of Percutaneous Coronary Interventions with Ultrathin Strut Biodegradable-Polymer Sirolimus-Eluting Stents—ORSHINE Registry

  AUTHORS: Sridhar Kasturi, Shailender Singh, S. Vijay Kumar Reddy, Kondalrao Gollamandala, Ganesh Mathan, Manikandhar Pendyala, Chandrashekar Challa

  KEYWORDS: Ultra-Thin Struts, Biodegradable Polymer, Sirolimus-Eluting Stent

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.11 No.7, July 9, 2021

  ABSTRACT: Current new generation stent technology has made remarkable progress in stent design, structure, and component material to improve its performance in reducing stent thrombosis, and restenosis compared to earlier DES and BMS. Orsiro-Sirolimus eluting stent is new generation ultra-thin strut stent with biodegradable abluminal coating that leaves a polymer free stent after drug release enhances coverage of stent struts and prevents excess neo intimal proliferation. A retrospective data analysis was done to see safety and efficacy of Orsiro in patients treated with ultra-thin DES with Orsiro stents at Sunshine Hospitals, Hyderabad. A total of 331 patients with 525 lesions were treated with 506 Orsiro stents and the major adverse cardiac events (MACE) rate and stent thrombosis (ST) at 2 years’ follow-up were analysed. MACE rate was 1.6% for an average follow-up at 2 years. Out of 2 patients who developed ST, one presented with definite acute stent thrombosis and one with possible, late stent thrombosis and 1.8% non-cardiac death reported during the follow-up. Despite many patients with complex PCI in the ACS subset, Orsiro reduced significant reduction in MACE rate in all spectrum of coronary artery disease patients with excellent acute and long-term results similar to other established FDA-approved current generations stents.